Volume 35 Issue 6
Nov.  2019
Turn off MathJax
Article Contents
Article Navigation >  Journal of Nanjing University of traditional Chinese Medicine  > 2019  >  35(6): 646-650
ZHANGTao-tao, WANGLu-lu, XIAOYan-ping, LIAOLiang. Clinical Study on Guyang Huashui Formula in Treating Diabetic Macular Edema with Spleen and Kidney Yang Deficiency Type[J]. Journal of Nanjing University of traditional Chinese Medicine, 2019, 35(6): 646-650.
Citation: ZHANGTao-tao, WANGLu-lu, XIAOYan-ping, LIAOLiang. Clinical Study on Guyang Huashui Formula in Treating Diabetic Macular Edema with Spleen and Kidney Yang Deficiency Type[J]. Journal of Nanjing University of traditional Chinese Medicine, 2019, 35(6): 646-650.
shu

Clinical Study on Guyang Huashui Formula in Treating Diabetic Macular Edema with Spleen and Kidney Yang Deficiency Type

  • 1.

    The Second Clinical College of Medicine, Beijing University of Chinese Medicine, Beijing, 100078, China

  • 2.

    Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China

  • Publish Date: 2019-11-10
    Abstract
  • OBJECTIVE To evaluate the clinical efficacy of Guyang Huashui formula in treating diabetic macular edema (DME) with spleen and kidney yang deficiency type. METHODS A prospective randomized controlled trial was conducted to observe 66 patients (66 eyes) with DME outpatients in the department of ophthalmology in Dongfang Hospital from January in 2016 to December in 2018. Patients admitted to the study should meet the diagnostic criteria for moderate and worse international clinical classification of DME and traditional Chinese medicine (TCM) syndrome type of spleen and kidney yang deficiency. Randomly divided into the experimental group and the control group， 33 cases each， who were given Guyang Huashui formula granules or calcium hydroxybenzenesulfonate capsules and Maizhiling tablets for oral treatment for 3 months. The efficacy was evaluated according to the patient's best corrected visual acuity， macular retinal thickness and volume， and TCM syndrome scores. RESULTS 30 patients in each group completed all treatment and observation. After treatment， the best corrected visual acuity in both groups was significantly improved compared with that before treatment (P<0.05， P<0.01 ) and difference between groups has no significant meaning (P>0.05). The thickness of the retinal film in the macular center of the test group was significantly reduced (P<0.01 ). The thickness of the retinal membrane and the average thickness of the retinal membrane in the macular area of the two groups were significantly reduced (P<0.01)， and the test group was significantly better than the control group (P<0.01). In the trial group， the medical syndrome was clearly improved (P<0.05， P<0.01). The two groups were compared and the difference was significant (P<0.05， P<0.01). CONCLUSION Guyang Huashui formula can significantly improve DME patient's vision and reduced retinal thickness in the macular area so as to relieve their TCM syndrome.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    WONG TY， SUN J， KAWASAKI R， et al. Guidelines on diabetic eye care: The international council of ophthalmology recommendations for screening， follow-up， referral， and treatment based on resource settings[J]. Ophthalmology， 2018， 125(10):1608-1622.
    [2]
    SOLOMON SD， CHEW E， DUH EJ，et al. Diabetic retinopathy: A position statement by the American diabetes association [J]. Diabetes Care， 2017， 40(3):412-418.
    [3]
    YANG W， LU J， WENG J， et al. Prevalence of diabetes among men and women in China [J]. N Eng J Med， 2010，362(12):1090-1101.
    [4]
    洪天配，杨进. 中国糖尿病防治的转化医学研究:机遇与挑战[J]. 中华糖尿病杂志，2017， 9（12）：729-731.
    [5]
    中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014版)[J].中华眼科杂志，2014，50(11):851-863.
    [6]
    惠延年，王琳. 糖尿病视网膜病变和糖尿病黄斑水肿的国际临床分类法[J].中华医学信息导报，2004，19（10）：16.
    [7]
    彭清华. 中医眼科学[M].北京: 中国医药科技出版社，2016：176.
    [8]
    国家中医药管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社，2002:74-77.
    [9]
    BROWNING DJ， EDITOR.Diabetic Retinopathy， Evidence-Based Management[M]. New York: Springer Inc， 2010: 142-147.
    [10]
    VINORES SA， MCGEHEE R， LEE A， et al. Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats [J]. J Histochem Cytochem， 1990，38:1341-1352.
    [11]
    GANDORFER A. Role of vitreous in diabetic macular edema [J]. Retina， 2012， 32(S2):S211-215.
    [12]
    MIYAMOTO K，KHOSROF S， BURSELL SE， et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1)[J]. Am J Pathol， 2000，156:1733-1739.
    [13]
    LUND-ANDERSEN H. Mechanisms for monitoring changes in retinal status following therapeutic intervention in diabetic retinopathy [J]. Surv Ophthalmol， 2002，47(S2):270-277.
    [14]
    TANG J， KERN TS. Inflammation in diabetic retinopathy [J]. Prog Retin Eye Res， 2011，30:343-358.
    [15]
    NAGAOKA T，KITAYA N， SUGAWARA R， et al. Alteration of choroidal circulation in the foveal region in patients with type 2 diabetes [J]. Br J Ophthalmol， 2004， 88:1060-1063.
    [16]
    BROWNING DJ， GLASSMAN AR， AIELLO LP，et al. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema [J]. Ophthalmology， 2008，115:1366-1371.
    [17]
    ELIWA TF， HUSSEIN MA， ZAKI MA，et al. Outer retinal layer thickness as good visual predictor in patients with diabetic macular edema [J]. Retina， 2018，38:805-811.
    [18]
    MATURI RK， POLLACK A， UY HS， et al. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study [J]. Retina， 2016，36:1143-1152.
    [19]
    NGUYEN QD， BROWN DM， MARCUS DM， et al. Ranibizumab for diabetic macular edema: Results from 2 phase Ⅲ randomized trials: RISE and RIDE [J]. Ophthalmology， 2012，119:789-801.
    [20]
    BRESSLER NM， BEAULIEU WT， GLASSMAN AR， et al. Persistent macular thickening followingintravitreous aflibercept， bevacizumab， or ranibizumab for central-involved diabetic macular edema with vision impairment: A secondary analysis of a randomized clinical trial [J]. JAMA Ophthalmol， 2018，136:257-269.
    [21]
    SOHEILIAN M， GARFAMI KH， RAMEZANI A，et al. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema [J]. Retina， 2012，32:314-321.
    [22]
    FIGUEROA MS， CONTRERAS I，NOVAL S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema [J]. Retina， 2008，28:420-426.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (621) PDF downloads(488) Cited by()
    Proportional views
    Related

    Copyright © Journal of Nanjing University of traditional Chinese Medicine

    Sponsored by：Nanjing University of traditional Chinese MedicineAddress：No.138 xianlin Avenue, Qixia District, Nanjing cityChina Pos：210023

    Tel：025-85811935Email：xb@njucm.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return